Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: A correlative immunohistochemical study of 175 cases

Journal of Neuropathology and Experimental Neurology

Volumn 59, Issue 10, 2000, Pages 872-879

  Perry, Arie ^a   Cai, Dan X ^a   Scheithauer, Bernd W ^b   Swanson, Paul E ^a   Lohse, Christine M ^b   Newsham, Irene F ^c   Weaver, Amy ^b   Gutmann, David H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DAL 1; Hormone receptors; Immunohistochemistry; Malignant; Meningioma; NF2; Tumor suppressor gene

Indexed keywords

MERLIN; PROGESTERONE RECEPTOR;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; GENE EXPRESSION; GENE LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MENINGIOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0033786149     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/59.10.872     Document Type: Article

References (58)

1. Epidemiological study of primary intracranial tumours in elderly people
2. Descriptive epidemiology of primary brain and CNS tumors: Results from the Central Brain Tumor Registry of the United States, 1990-1994
3. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas
4. Deletion mapping of the long arm of chromosome 22 in human meningiomas
5. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas
6. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors
7. Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas
8. Molecular genetic investigation of the NF2 tumor suppressor gene in sporadic meningioma
9. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas
10. Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas
11. Expression of neurofibromatosis 2 protein in human brain tumors: An immunohistochemical study
12. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas
13. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas
14. Allelic losses in neurofibromatosis 2-associated meningiomas
15. Allelic loss on chromosome 22 correlates with histopathological predictors of recurrence of meningiomas
16. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas
17. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression
18. Frequent loss of chromosome 14 in atypical and malignant meningioma: Identification of a putative 'tumor progression' locus
19. Loss of heterozygosity of chromosome 14q in low- and high-grade meningiomas
20. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas
21. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma
22. Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants
23. A novel member of the NF2/ERM/4. 1 superfamily with growth suppressing properties in lung cancer
24. Loss of DAL-1, a second protein 4. 1 tumor suppressor, is an important early event in the pathogenesis of meningioma
25. Estrogen and progesterone receptors in meningiomas: Comparison of nuclear binding, dextran-coated charcoal, and immunoperoxidase staining assays
26. Immunohistochemical detection of female sex hormone receptors in meningiomas: Correlation with clinical and histological features
27. Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: Immunocytochemical assays in 52 meningiomas
28. Progesterone and glucocorticoid receptor activation in meningiomas
29. Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas
30. The molecular biology of hormone and growth factor receptors in meningiomas
31. Progesterone and estrogen receptors in meningiomas: Prognostic considerations
32. Prolactin receptors in human meningiomas: Characterization and biological role
33. Meningiomas and hormonal receptors. Immunohistochemical study in typical and non-typical tumors
34. Progesterone receptor synthesis in human meningiomas: Relation to the estrogen-induced proteins pS2 and cathepsin-D and influence of epidermal growth factor, Forskolin and phorbol ester in vitro
35. Meningioma grading: An analysis of histologic parameters
36. 'Malignancy' in meningiomas: A clinicopathologic study of 116 patients
37. Meningiomas
38. Neurofibromatosis 2: Loss of merlin's protective spell
39. Defects in neurofibromatosis 2 protein function can arise at multiple levels
40. Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading
41. Lack of p16(INK4) or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines
42. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
43. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas
44. Neoplasms of the central nervous system in Norway. An analysis of the occurrence of multiple primary neoplasms in meningioma patients in Norway from 1955 through 1986
45. Association of breast cancer and meningioma. Report of 12 new cases and review of the literature
46. Association of breast carcinoma and meningioma: Report of nine new cases and review of the literature
47. Hormonal manipulation of meningiomas in vitro
48. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone
49. Mifepristone (RU 486) treatment of meningiomas
50. Role of antiprogestational therapy for meningiomas
51. Management of benign and aggressive intracranial meningiomas
52. Immunocytochemical study of progesterone receptor in human meningioma
53. The prognostic role of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas
54. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas
55. Cytogenetic analysis of aggressive meningiomas
56. Deletion mapping of the short arm of chromosome 1 identifies a common region of deletion distal to D1S496 in human meningiomas
57. Identification of a consistent region of allelic loss on 1p32 in meningiomas